Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis

Zhong Guo Liang¹, Guo Xiang Lin¹, Jia Xiang Ye², Ye Li¹, Ling Li¹, Song Qu¹, Xia Liang¹, Xiao Dong Zhu¹*

Abstract

Background: It is unclear whether Cetuximab (CTX) or Nimotuzumab (NTZ) concurrent with radiotherapy delivers equivalent or improved results with fewer toxicities over standard cisplatin (CDDP) concurrent with radiotherapy in locally advanced nasopharyngeal carcinoma (NPC). Methods: The strategy involved searching the PubMed, Embase, Cochrane Library, China National Knowledge Internet Web, Wanfang and Chinese Biomedical databases. Controlled clinical trials that compared concurrent CTX/NTZ with radiotherapy versus CDDP with radiotherapy in locally-advanced NPC were included. Results: In all, 1,239 patients in six clinical trials were included in the analysis. The hazard ratios (HRs) between the CTX/NTZ and CDDP groups were 1.01 (95% confidence interval (CI) 0.63-1.64), 1.06 (95% CI 0.50-2.25), 1.04 (95% CI 0.61-1.76), and 1.05 (95% CI 0.73-1.50) for overall survival, local-regional failure-free survival, distant metastasis failure-free survival, and disease-free survival, respectively. Significant differences were found in the incidences of grade 3-4 anaemia [Risk ratio (RR) 0.11 95% CI 0.02-0.58], grade 3-4 neutropenia (RR 0.23 95% CI 0.12-0.44), grade 3-4 thrombocytopenia (RR 0.31 95% CI 0.12-0.79), and grade 3-4 vomiting (RR 0.04 95% CI 0.00-0.29) in favour of the CTX/NTZ group. However, the patients in the CTX/NTZ group experienced a higher incidence of grade 3-4 skin rash (RR 6.45 95% CI 3.84-10.84). Conclusions: Regarding the efficacy and side effects, the combination of CTX/NTZ and radiotherapy may be an alternative treatment regimen of standard CDDP concurrent with radiotherapy in local-regionally advanced NPC, especially in patients who cannot tolerate or who refuse chemotherapy.

Keywords: Nasopharyngeal neoplasms- cetuximab- nimotuzumab- radiotherapy- meta-analysis

Introduction

The incidence rate of nasopharyngeal carcinoma (NPC) is high in Malaysia, Indonesia, Singapore, and south-eastern China (Torre et al., 2015). According to the National Comprehensive Cancer Network (version 1, 2017), a cisplatin (CDDP)-based concurrent chemoradiotherapy (CCRT) regimen is recommended as the standard treatment for locally-advanced NPC (category 2A). However, CDDP-based concurrent chemotherapy is often associated with high rates of grade 3-4 gastrointestinal and haematological toxicities that severely affect quality of life and medication compliance (Chan et al., 2002; Liao et al., 2016; You et al., 2017). More than 80% of patients with NPC express the epidermal growth factor receptor (EGFR) (Taheri-Kadhoda et al., 2009; Cao et al., 2012; Zhang et al., 2015). The addition of anti-EGFR monoclonal antibodies to radiotherapy (RT) improved survival in patients with locally-advanced squamous-cell carcinoma of the head and neck (SCCHN) (Bonner et al., 2006; Bonner et al., 2010). These findings prompted researchers to investigate whether replacing concurrent chemotherapy with anti-EGFR monoclonal antibodies to treat local-regionally advanced NPC is feasible and whether it would reduce treatment toxicity but not therapeutic effects.

Recently, several studies compared efficacy and safety between RT plus cetuximab (CTX) or nimotuzumab (NTZ) therapy and RT plus CDDP therapy in locally-advanced NPC (Xu et al., 2015; Li et al., 2016; Liao et al., 2016; Wu et al., 2016; You et al., 2017). You et al. (2017) retrospectively compared efficacy and safety between RT plus CTX/NTZ and RT plus CDDP in locally-regionally...
advanced NPC. The two groups exhibited comparable rates of disease-free survival (DFS), local-regional failure-free survival (LRFS), distant metastasis failure-free survival (DMFS), and overall survival (OS). Nevertheless, in a trial conducted by Li et al., the 5-year OS and DFS rates were significantly lower in the NTZ group than in the CDDP group (Li et al., 2016). However, the sample sizes in these studies were small.

Thus, whether CTX/NTZ is an effective and safe alternative to CDDP is a compelling question for further studies. We therefore conducted a literature-based meta-analysis to investigate whether CTX/NTZ concurrent with RT achieves results that are equivalent to or better than those achieved by a standard CDDP concurrent with RT regimen in local-regionally advanced NPC. We also evaluated the incidences of toxicities.

Materials and Methods

Literature search strategy

The literature search was performed using the PubMed, Embase, Cochrane Library, China National Knowledge Internet Web (CNKI), Chinese Biomedical (CBM), and Wanfang databases. The search was performed using the following terms: nasopharyngeal carcinoma OR nasopharyngeal cancer OR nasopharyngeal tumour OR nasopharyngeal neoplasms, cetuximab OR nimotuzumab OR target, and radiotherapy. We searched for trials published and/or presented by 15 July 2017. In addition, the reference lists of the selected works were scanned to identify additional relevant articles. The Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University approved this meta-analysis.

Inclusion and exclusion criteria

Trials were included if they met the following criteria: (1) the participating patients had local-regionally advanced NPC; (2) the studies compared CTX/NTZ and CDDP; and (3) the studies were controlled clinical trials, including RCTs, retrospective controlled trials or matched-pair analyses. However, the following were applied as exclusion criteria: (1) the study was not a controlled clinical trial; (2) the study was missing important information; and (3) the article was a review, letter, case report, meeting abstract, or trial protocol or comments. Eligible trials were independently identified by two reviewers, and discussions were resolved by a third person.

Quality assessment

The selected retrospective trials were evaluated and their results quantified using the 9-star Newcastle-Ottawa Scale (Wells et al., 2011). The quality of the RCTs was assessed using the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Julian and Sally, 2011). The risk of bias in the RCTs was determined by scoring the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. The risk of bias was evaluated as high risk, low risk, or unclear according to these criteria. The quality of the included trials was independently assessed by two investigators. Any disagreements that arose during this procedure were resolved by consensus.

Data extraction

Information regarding the first author, study year, design type, inclusion period, number of patients in each of the CTX/NTZ and CDDP groups, clinical stage, regimen of RT, chemotherapy and target therapy was extracted from each study. Additionally, the primary and secondary end points, including the HRs of OS, LRFS, DMFS, DFS and haematological and non-haematological adverse events, were also extracted. If an HR and corresponding 95% confidence interval (CI) could not be obtained directly from the original trial, they were indirectly extracted from Kaplan-Meier curves as reported by Tierney et al. (Tierney et al., 2007).

Statistical analysis

OS, LRFS, DMFS, and DFS were calculated as HRs and 95% CIs to determine differences between the CTX/NTZ and CDDP groups. If HRs and 95% CIs could not be directly or indirectly obtained, risk ratios (RRs) and corresponding 95% CIs were calculated. Additionally, haematological and non-haematological adverse events were assessed as RRs with 95% CIs.

We evaluated the heterogeneity of the results using the I2 statistic to calculate inconsistency. An I2 ≥ 50% indicated statistically significant heterogeneity. A fixed-effects model was applied if the heterogeneity test showed that there was no statistical significance (I2 < 50%; P > 0.1). Otherwise, the following analyses were performed: (1) a sensitivity analysis was performed by excluding studies with potentially biased results; and (2) if statistically significant heterogeneity still existed, a random-effects model was used. All analyses were conducted using Stata version 12.0 software (StataCorp, College Station, Texas).

Results

Study selection and characteristics

Using the search criteria, we screened 2,334 records. Of these, 640 were duplicates. After we reviewed the titles and abstracts, 1,684 irrelevant publications were excluded. Additionally, four studies were excluded after the full text was reviewed. One study was a clinical trial with only a single arm (Niu et al., 2013). Another study included a control group that received only RT (Huang et al., 2007). In the study performed by Luo et al. (Luo et al., 2016), the concurrent chemotherapy regimen used in the control group was not CDDP. In the study conducted by Xia et al., the regimen used in the experimental group was a combination of CTX with chemoradiotherapy (Xia et al., 2017). Finally, 1,239 patients in six clinical controlled trials (Yin et al., 2014; Xu et al., 2015; Li et al., 2016; Liao et al., 2016; Wu et al., 2016; You et al., 2017) were included in the analysis, with 368 patients in the CTX/NTZ arm and 871 patients in the CDDP arm. A flow diagram demonstrating the process is shown in Figure 1.

Detailed information regarding the selected studies
Nasopharyngeal Carcinoma

Quality assessment of the included studies

Of the six studies, four were retrospective controlled trials, and two were RCTs. The quality of the retrospective studies was determined according to the 9-star Newcastle-Ottawa Scale. All included studies were evaluated as high quality on this scale. In the two RCTs, random sequence generation, allocation concealment, and other biases were assessed as unclear (Xu et al., 2015; Liao et al., 2016). For the criteria related to selective reports, one study was considered high risk (Liao et al., 2016), and another study was considered low risk (Xu et al., 2015). Both of these trials were considered low risk for complete outcome data, blinding of participants and personnel, and blinding of outcome assessments (Xu et al., 2015; Liao et al., 2016).

Efficacy (Figure 2)

Data regarding the OS were available in four trials involving 319 patients in the CTX/NTZ group and 816

Figure 1. Selection Process for Clinical Controlled Trials Included in the Meta-analysis

Figure 2. Forest Plots of the HRs for OS, LRFS, DMFS, and DFS in the CTX/NTZ Group and the CDDP Group

Figure 3. Forest Plots of the RRs for Grade 3-4 Anaemia, Neutropenia, and Thrombocytopenia in the CTX/NTZ Group and the CDDP Group

Figure 4. Forest Plots of the RRs for Grade 3-4 Vomiting, Mucositis, Skin Rash, and Weight Loss in the CTX/NTZ Group and the CDDP Group
patients in the CDDP group (Yin et al., 2014; Li et al., 2016; Wu et al., 2016; You et al., 2017). No significant heterogeneity was detected ($I^2 = 0.0\%$, $P = 0.641$); and a fixed-effects model was therefore used. There was no significant difference in OS between the CTX/NTZ group and the CDDP group (HR 1.01, 95% CI 0.63 - 1.64).

Data regarding 3-year OS were provided in two trials [11, 12]. These trials contributed 77 CTX group patients and 79 CDDP group patients. There was no significant difference in 3-year OS between the CTX group and the CDDP group (RR: 0.83 95% CI 0.25-2.79; heterogeneity: $P = 0.561$, $I^2 = 0\%$).

**LRFS**
The pooled results (963 patients in 3 trials) (Yin et al., 2014; Xu et al., 2015; You et al., 2017) revealed that there was no significant difference in LRFS between the CTX/NTZ group and the CDDP group (HR: 1.06, 95% CI 0.50 – 2.25; heterogeneity: $I^2 = 0\%$, $P = 0.801$).

**DMFS**
DMFS data were reported in three trials involving 232 patients in the CTX/NTZ group and 731 patients in the CDDP group (Yin et al., 2014; Xu et al., 2015; You et al., 2017). There was no significant difference in DMFS between the two groups (HR: 1.04, 95% CI 0.61-1.76; heterogeneity: $I^2 = 0\%$, $P = 0.456$).

**DFS**
DFS data were available in five trials involving 340 CTX/NTZ group patients and 839 CDDP group patients (Yin et al., 2014; Xu et al., 2015; Li et al., 2016; Wu et al., 2016; You et al., 2017). There was no significant difference in DFS between the two groups (HR: 1.05, 95% CI 0.73-1.50; heterogeneity: $I^2 = 0\%$, $P = 0.581$).

**Toxicity**

**Grade 3-4 haematological toxicity**
Two studies provided information regarding grade 3-4 anaemia (Liao et al., 2016; You et al., 2017), three studies provided information regarding grade 3-4 neutropenia (Xu et al., 2015; Liao et al., 2016; You et al., 2017), and three studies provided information regarding grade 3-4 thrombocytopenia (Li et al., 2016; Liao et al., 2016; You et al., 2017). Compared with the CDDP group, the CTX/NTZ group exhibited a lower risk of experiencing grade 3–4 toxic events, including anaemia (RR: 0.11, 95% CI 0.02-0.58; heterogeneity: $P = 0.830$, $I^2 = 0\%$), neutropenia (RR: 0.23, 95% CI 0.12-0.44; heterogeneity: $P = 0.147$, $I^2 = 47.9\%$), and thrombocytopenia (RR: 0.31 95% CI 0.12-0.79; heterogeneity: $P = 0.508$, $I^2 = 0\%$) (Figure 3). A subgroup analysis showed that patients in the NTZ group had a lower risk of experiencing grade 3–4 toxic events, including anaemia (RR: 0.14, 95% CI 0.03-0.71; heterogeneity: $P = 0.929$, $I^2 = 0\%$) and thrombocytopenia (RR: 0.30 95% CI 0.11-0.88; heterogeneity: $P = 0.485$, $I^2 = 10.0\%$), but there was no significant difference in the incidence of grade 3-4 neutropenia (RR: 0.35, 95% CI 0.10-1.20; heterogeneity: $P = 0.094$, $I^2 = 64.3\%$; random-effects model) (Figure 5). However, there was a lower risk of grade 3–4 toxic neutropenia in the CTX group than in the CDDP group (RR: 0.16, 95% CI 0.04-0.56; heterogeneity: $P = 0.592$, $I^2 = 0\%$) (Figure 6).

**Grade 3-4 vomiting**
Two trials contributed information regarding
Table 1. Inclusion Criteria of Eligible Trials

| Study | Design type | No. of patients | Inclusion period | Stage | Radiotherapy | Induction Chemotherapy | Concurrent Chemotherapy | Target therapy |
|-------|-------------|-----------------|-----------------|-------|--------------|------------------------|--------------------------|---------------|
| Yin,2014 | Retrospective | 68 / 136 | 2008-2012 | II-IV B | IMRT: PTVG: 69.96 Gy, PTV1: 60.06 Gy, PTV2: 50.96 Gy | none | CDDP | CTZ: 400 mg/m² for the first week, then 250 mg/m²/week NTZ: 200 mg/week |
| Li,2016 | Retrospective | 52 / 52 | 2008-2013 | II-IV B | IMRT: 2.12-2.24 Gy/F, 5 F/week, to 70–74 Gy | TPF: DOC 75 mg/m², CDDP 25 mg/m²/d 1-3, 5-Fu 600 mg/m² d1-5 | CDDP 25 mg/m²/d 1-3, q3wks | NTZ: 200 mg/week |
| Wu,2016 | Retrospective | 56 / 56 | 2008-2012 | II-IV B | IMRT: 2.12-2.24 Gy/F, 5 F/week, to 70–74 Gy | TPF: Ptx 75 mg/m², CDDP 25 mg/m²/d 1-3, 5-Fu 600 mg/m² d1-5 | CDDP 25 mg/m²/d 1-3, q3wks | NTZ: 400 mg/m² for the first week, then 250 mg/m²/week NTZ: 200 mg/week |
| You,2017 | Retrospective | 143 / 572 | 2009-2013 | II-IV B | IMRT: PGTVin: 66-70 Gy, PTVG: 28-33 Gy, PGTVnd: 60-66 Gy, PTV1: 60 Gy, PTV2: 54 Gy, PTV2: 54 Gy | PF: CDDP 80-100 mg/m² d1, 5-Fu 800 mg/m² d1-5 | TP: DOC 75 mg/m², CDDP 75 mg/m² d1, TPF: DOC 60 mg/m², CDDP 60 mg/m², 5-Fu 600 mg/m² d1-5 | Cisplatin 100 mg/m² d1, q3wks |
| Xu,2015 | Prospective | 21 / 23 | 2010-2011 | III-IV B | IMRT: PGTVin: 66-70 Gy, PTV1: 60 Gy, PTV2: 54 Gy, GTVNd: 60 Gy, PTV1: 60 Gy, PTV2: 54 Gy | TP: DOC 75 mg/m², CDDP 80 mg/m² d1 | CDDP 30 mg/m² d1, qwk | CTZ: 400 mg/m² for the first week, then 250 mg/m²/week NTZ: 200 mg/week |
| Liao,2016 | Prospective | 28 / 32 | 2012-2013 | III-IV B | IMRT: PGTVin: 70 Gy, PTV1: 61.25 Gy, PTV2: 54 Gy | TPF: DOC 75 mg/m², CDDP 25 mg/m²/d 1-3, 5-Fu 2500 mg/m³ GTV nd 120h | CDDP 40 mg/m² d1, qwk | NTZ: 200 mg/week |

CTX, Cetuximab; NTZ, Nimotuzumab; CDDP, Cisplatin; IC, Induction chemotherapy; RT, Radiotherapy; AJCC, American Joint Committee on Cancer; IMRT, Intensity modulated radiation therapy; DOC, Docetaxel; 5-Fu, 5-Fluorouracil; PTX, Paclitaxel; GTVnx, Gross target volume of the nasopharynx; GTVnd, Gross target volume of lymph node; PTV, Planning target volume

grade 3–4 vomiting in 171 patients in the CTX/NTZ group and 604 patients in the CDDP group (Liao et al., 2016; You et al., 2017). There were significantly fewer such events in the CTX/NTZ group (RR: 0.04, 95% CI 0.00-0.29, heterogeneity P = 0.825, I² = 0.0%) (Figure 4). A subgroup analysis showed that patients in the NTZ group were at lower risk than the CDDP group patients of experiencing grade 3–4 vomiting (RR: 0.05, 95% CI 0.01-0.39; heterogeneity: P = 0.963, I² = 0%) (Figure 5).

Grade 3-4 mucositis

Five trials contributed 1,035 patients for whom information was provided regarding grade 3-4 mucositis (Xu et al., 2015; Li et al., 2016; Liao et al., 2016; Wu et al., 2016; You et al., 2017). The risk of grade 3-4 mucositis was significantly higher in the CTX/NTZ group than in the CDDP group (RR: 1.24, 95% CI 1.05-1.45). However, significant heterogeneity was observed (heterogeneity: P = 0.04, I² = 61.0%). A sensitivity analysis resulted in the exclusion of one trial (Wu et al., 2016). Finally, a non-significant trend towards higher grade 3-4 mucositis was observed in the CTX/NTZ group (RR: 1.13, 95% CI 0.94-1.36; heterogeneity: P = 0.155, I² = 42.7%) (Figure 4).

A subgroup analysis showed that patients in the CTX group had a higher risk than those in the CDDP group of experiencing grade 3-4 mucositis (RR: 1.62 95% CI 1.33-1.98; heterogeneity: P = 0.760, I² = 0%) (Figure 6), but there was no significant difference between the NTZ group and the CDDP group (RR: 0.92 95% CI 0.72-1.18; heterogeneity: P = 0.94-1.36; heterogeneity: P = 0.155, I² = 42.7%) (Figure 4).

Grade 3-4 skin rash

Four trials contributed information regarding grade 3-4 skin rash in 244 patients in the CTX/NTZ group and 679 patients in the CDDP group (Xu et al., 2015; Li et al., 2016; Liao et al., 2016; You et al., 2017), and there were significantly more such cases in the CDDP
group (RR 4.39 95% CI 2.80-6.87). However, significant heterogeneity was observed (heterogeneity: $P = 0.02$, $I^2 = 70.0$%). A sensitivity analysis resulted in the exclusion of one trial (Liao et al., 2016). Finally, we found that there was a significantly higher risk of this side-effect in the CTX/NTZ group (RR: 6.45, 95% CI 3.84-10.84; heterogeneity: $P = 0.707$, $I^2 = 0.0$%) (Figure 4). A subgroup analysis showed that patients in the CTX group were at higher risk than patients in the CDDP group of experiencing a grade 3-4 skin rash (RR: 11.41 95% CI 6.35-20.52; heterogeneity: $P = 0.745$, $I^2 = 0.0$%) (Figure 6), but there was no significant difference between the NTZ group and the CDDP group (RR: 1.32 95% CI 0.22-8.06; heterogeneity: $P = 0.062$, $I^2 = 64.0$%; random-effects model) (Figure 5).

**Grade 3-4 weight loss**

Three trials reported information regarding grade 3-4 weight loss for 251 patients in the CTX/NTZ group and 680 patients in the CDDP group (Li et al., 2016; Wu et al., 2016; You et al., 2017). The incidence of grade 3-4 weight loss was comparable between the two groups (RR: 0.96, 95% CI 0.64-1.45; heterogeneity: $P = 0.321$, $I^2 = 11.9$%) (Figure 4). A subgroup analysis showed that there was no significant difference between the CTX group and the CDDP group (RR: 1.16 95% CI 0.68-1.99; heterogeneity: $P = 0.490$, $I^2 = 0.0$%) or between the NTZ group and the CDDP group (RR: 0.78 95% CI 0.42-1.47; heterogeneity: $P = 0.483$, $I^2 = 0.0$%) (Figure 5 and Figure 6).

**Discussion**

To the best of our knowledge, this study is the first meta-analysis to compare the efficacy and toxicity of CTX/NTZ to those of CDDP concurrent with RT in local-regionally advanced NPC.

A combination therapy including anti-EGFR monoclonal antibodies and RT has been shown to improve survival in patients with local-regionally advanced HNSCC (Bonner et al., 2006; Curran et al., 2007; Bonner et al., 2010; Rodriguez et al., 2010). These reports have supported the notion that anti-EGFR monoclonal antibodies may also be used as an alternative to CDDP for definitive concurrent chemoradiotherapy in local-regionally advanced NPC. A randomized phase II study was conducted to evaluate the clinical efficacy and toxicity of induction chemotherapy followed by concomitant CDDP-chemoradiotherapy or CTX-RT in local-regionally advanced NPC (Xu et al., 2015). The results showed that the 3-year DFS, LRFS, DMFS, and OS rates were similar between the two groups. Nevertheless, Li et al., (2016) compared a NTZ group and a CDDP group and found that five-year OS and DFS were significantly higher in the CDDP group. It is therefore essential that prospective randomized controlled studies be performed to compare CTX/NTZ combined with RT to standard CCRT in local-regionally advanced NPC.

The overexpression of EGFR has been associated with an increased risk of both distant metastasis and radiation resistance (Cao et al., 2012; Sun et al., 2014). Hence, inhibiting EGFR may benefit affected patients by reducing the rate of distant metastasis and local-regional recurrence. In the present study, there was no significant difference in DMFS and LRFS between the CTX/NTZ group and the CDDP group. There are several potential explanations for this finding. First, the prognosis is worse in patients positive for EGFR expression than in those without (Cao et al., 2012; Sun et al., 2014). The rate of EGFR expression is high in NPC (Taheri-Kadkhoda et al., 2009; Zhang et al., 2015), and the improvements observed following treatment with CTX/NTZ might have been mitigated by the poorer prognosis reported in these patients. Second, several RCTs and meta-analyses have demonstrated that concurrent chemotherapy reduces the risk of both distant metastasis and local-regional recurrence in local-regionally advanced NPC (Lin et al., 2003; Lee et al., 2011; Blanchard et al., 2015; Yan et al., 2015). This reduced risk may have contributed to the negative results in the survival analysis. Moreover, induction chemotherapy has been demonstrated to improve both DMFS and LRFS (Song et al., 2015; Sun et al., 2016; Cao et al., 2017). Patients underwent induction therapy in five of the included trials, and the inclusion of these patients may have narrowed the effects of CTX/NTZ more than the effects of CDDP.

The present meta-analysis showed that fewer adverse events, including grade 3-4 anaemia, neutropenia, thrombocytopenia, and vomiting, occurred in the CTX/NTZ group. Therefore, to a certain degree, CTX/NTZ plus RT may be associated with better medication compliance among patients (Kong et al., 2015; Xu et al., 2015; Liao et al., 2016). However, the patients in the CTX/NTZ group, and especially those in the CTX group, experienced a higher rate of grade 3-4 skin rashes. Fortunately, these events are not severe enough to be life-threatening and are therefore less likely to result in the discontinuation of drug delivery (Bernier and Schneider, 2007; Curran et al., 2007). These side-effects frequently resolve after 3 months and do not cause long-term dysfunctions (Xu et al., 2015). Hence, CTX or NTZ may be an ideal alternative to CDDP in terms of adverse events.

There are several limitations to our meta-analysis. First, because all information was extracted from publications and we lacked access to individual patient data, it is possible that publication, reporting or selection bias may have occurred. Second, four of the included studies were retrospective trials in which the patients met specific selection criteria, and this may have resulted in selection bias. Third, some of the studies did not directly provide HRs and 95% CIs for OS, DFS, LRFS or DMFS. Two authors of the current study independently extracted the missing HRs from survival curves, and disagreements were resolved by a third person. However, errors may have occurred.

In conclusion, the efficacy of and side effects associated with CTX/NTZ combined with RT indicated that this treatment may be an alternative regimen to standard CDDP concurrent with RT in patients with local-regionally advanced NPC, especially in patients who cannot tolerate or who refuse chemotherapy. However, the high rate of grade 3-4 skin rash should not be ignored. Therefore, multicentre, prospective, randomized controlled clinical
trials are needed to fully explore the usefulness of this treatment in this group of patients.

Conflict of interest
The authors declare they have no conflicts of interest.

Acknowledgements
This work was sponsored by grants from the National Natural Science Foundation of China (No. 81760544), Basic Ability Enhancement Project of Young Teachers in Guangxi Zhuang Autonomous Region (No. 2017KY0114), and the Youth Science Found of Guangxi Medical University (No. GXMUYSF201515).

References

Bernier J, Schneider D (2007). Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?: Eur J Cancer, 43, 35-45.

Blanchard P, Lee A, Marguet S, et al (2015). Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol, 16, 645-55.

Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.

Bonner JA, Harari PM, Giralt J, et al (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11, 21-8.

Cao SM, Yang Q, Guo L, et al (2017). Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer, 75, 14-23.

Cao XJ, Hao JF, Yang XH, et al (2012). Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol, 29, 263-71.

Chan AT, Teo PM, Ngan RK, et al (2002). Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol, 20, 2038-44.

Curran D, Giralt J, Harari PM, et al (2007). Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol, 25, 2191-7.

Huang X, Yi J, Gao L, et al (2007). Milli-center phase- clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Oncol, 29, 197-201.

Julian P, Sally G (2011). Cochrane handbook for systematic review of interventions version 5.0.1. The cochrane collaboration. Available: http://www.cochranehandbook.org.

Kong L, Lin Q, Hu C, et al (2015). Radiation plus concurrent nimotuzumab versus cisplatin-based chemotherapy in locally advanced nasopharyngeal cancer: An interim analysis of a phase 3 randomized clinical trial. Int J Radiat Oncol Biol Phys, 93, S129.

Lee AW, Tung SY, Ngan RK, et al (2011). Factors contributing to the efficacy of concurrent-adjunct chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer, 47, 656-66.

Li HM, Li P, Qian YJ, et al (2016). A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. BMC Cancer, 16, 946.

Liao X, Kong L, Zheng H, et al (2016). Comparison of efficacy and adverse reactions between radiotherapy combined with cisplatin and radiotherapy combined with nimotuzumab in treatment of locally advanced nasopharyngeal carcinoma Chin J Radiat Oncol, 25, 1277-80.

Lin JC, Jan JS, Hsu CY, et al (2003). Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol, 21, 631-7.

Luo Y, Yang G, Lang J (2016). Clinical outcomes and prognostic factors of cetuximab plus intensity modulated radiotherapy with chemotherapy for nasopharyngeal carcinoma J Canc Control Treat, 29, 17-22.

Niu X, Hu C, Kong L (2013). Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 139, 1063-71.

Rodriguez MO, Rivero TC, del Castillo Bahi R, et al (2010). Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther, 9, 343-9.

Song Y, Wang W, Tao G, et al (2015). Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma-A time-to-event meta-analysis. Oral Oncol, 51, 764-9.

Sun W, Long G, Wang J, et al (2014). Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis. Head Neck, 36, 1508-16.

Sun Y, Li WF, Chen NY, et al (2016). Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol, 17, 1509-20.

Taheri-Kadkhoda Z, Magnusson B, Svensson M, et al (2009). Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck, 31, 482-92.

Tierney JF, Stewart LA, Gchersi D, et al (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.

Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.

Wells G, Shea B, D OC (2011). The Newcastle-Scale for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute.

Wu X, Huang J, Liu L, et al (2016). Cetuximab concurrent with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study. Medicine (Baltimore), 95, e4926.

Xia WX, Liang H, Lv X, et al (2017). Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis. Oral Oncol, 67, 167-74.

Xu T, Liu Y, Dou S, et al (2015). Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study. Oral Oncol, 51, 875-9.

Yan M, Kumachev A, Shi LL, et al (2015). Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal
carcinoma: A Bayesian network meta-analysis. *Eur J Cancer*, **51**, 1570-9.

Yin Z, Yi J, Huang X, et al (2014). Clinical effects of IMRT combined with EGFR monocional antibody, concurrent chemoradiotherapy, and IMRT alone in nasopharyngeal carcinoma patients-a retrospective case-control study. *Chin J Radiat Oncol*, **23**, 495-9.

You R, Sun R, Hua YJ, et al (2017). Cetuximab or nimutuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. *Int J Cancer*, **141**, 1265-76.

Zhang P, Wu SK, Wang Y, et al (2015). p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. *Oncol Lett*, **9**, 113-8.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.